700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Reports Second-Quarter 2026 Financial Results and Provides Business Update—Total Revenues of $425.5 Million for the Second Quarter of 2026——Revenues of $309.2 Million for the Second Quarter of 2026, Reflecting 49% Growth Over the First Quarter of 2026—Revenue Guidance to $1.25 Billion to $1.40 Billion——Reiterates Revenue Guidance of $450 Million to $470 Million——Rais
Investor Presentation
Shareholders Elect Elizabeth McKee Anderson and Clarissa Desjardins as Directors
Reports First-Quarter 2026 Financial Results and Provides Business Update
Provides Clinical Update on Phase 2b CEDAR Study—Study Did Not Meet Primary or Secondary Efficacy Endpoints; Will Discontinue HS Program——Safety Was Consistent with Previous Studies and No New Safety Signals Were Identified for Either Dose of Brensocatib
Annual Report to Security Holders
Insmed 2025 Financial Results and 2026 Revenue Projections
Q2
Q1
FY 2024
Q3
FY 2023
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Free Writing Prospectus